157 E 32nd St. New York, NY 10016 212-689-6791

Welcome to the AML (Acute Myeloid Leukemia) Clinical Trial at MHOA in New York City

Now enrolling patients for a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are not eligible for intensive induction therapy.

The study will evaluate treatments with:
ASP2215 (Gilteritinib)
ASP2215 Plus Azacitidine
Azacitidine Alone

Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD), as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in 1/3 of patients with Acute Myeloid Leukemia.

MHOA Principle Investigator
Alec Goldenberg, M.D. 

For additional information contact:
Phenoia Browne, Clinical Trials Coordinator
Phone: 212-689-6791 ext 228
Email: clinicaltrials@mhony.com

AML- FLT3/IDT

Now enrolling patients for a phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215)…

Read More

CLL

Now enrolling patients for the InformCLL Registry, which is to characterize and describe treatment patterns for those initiating treatment with…

Read More

Mantle Cell Lymphoma

Now enrolling patients in a phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of…

Read More

Hodgkin Lymphoma

The objectives of this molecular profiling protocol are to describe current treatment patterns and consequences from first-line treatment

Read More